A detailed history of Engineers Gate Manager LP transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 25,806 shares of AGIO stock, worth $1.15 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
25,806
Previous 36,570 29.43%
Holding current value
$1.15 Million
Previous $1.07 Million 4.02%
% of portfolio
0.03%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$27.55 - $48.83 $296,548 - $525,606
-10,764 Reduced 29.43%
25,806 $1.11 Million
Q1 2024

May 15, 2024

BUY
$21.32 - $34.81 $255,498 - $417,163
11,984 Added 48.74%
36,570 $1.07 Million
Q4 2023

Feb 14, 2024

BUY
$19.97 - $24.53 $490,982 - $603,094
24,586 New
24,586 $547,000
Q3 2021

Nov 15, 2021

SELL
$41.92 - $58.18 $695,997 - $965,962
-16,603 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $12,025 - $14,153
-231 Reduced 1.37%
16,603 $915,000
Q1 2021

May 17, 2021

BUY
$44.23 - $57.5 $439,380 - $571,205
9,934 Added 143.97%
16,834 $869,000
Q4 2020

Feb 16, 2021

SELL
$33.21 - $46.54 $305,465 - $428,074
-9,198 Reduced 57.14%
6,900 $299,000
Q3 2020

Nov 16, 2020

BUY
$33.87 - $55.93 $368,708 - $608,853
10,886 Added 208.86%
16,098 $563,000
Q2 2020

Aug 17, 2020

BUY
$34.45 - $53.48 $179,553 - $278,737
5,212 New
5,212 $279,000
Q1 2020

May 15, 2020

SELL
$31.52 - $53.81 $573,033 - $978,265
-18,180 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$30.08 - $50.59 $118,244 - $198,869
3,931 Added 27.59%
18,180 $868,000
Q3 2019

Nov 14, 2019

BUY
$32.4 - $49.58 $461,667 - $706,465
14,249 New
14,249 $462,000
Q2 2019

Aug 14, 2019

SELL
$46.17 - $68.1 $189,297 - $279,210
-4,100 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$45.92 - $67.67 $188,272 - $277,447
4,100 New
4,100 $277,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $2.44B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.